Du är här



* Consolidated revenues € 1,047.7 million, +6.1%.
* EBITDA(1)€ 317.0 million, +15.8%
* Operating income € 278.5 million, +20.6%.
* Net income € 198.8 million, +23.3%.
* Net financial position(2): net debt of € 88.7 million.
* Further internationalization of business dedicated to rare diseases with
new subsidiaries in Brazil, Mexico and Colombia.
* Launch of Virirec®, a new treatment for erectile dysfunction, in Spain.
* Marketing Authorization Application submitted to EMA by Erytech Pharma for
* Targets for 2016.

Milan, 11 February 2016 -
The Board of Directors of Recordati S.p.A. examined the preliminary
consolidated results for 2015 and the group's objectives for the 2016. The
company's consolidated annual financial reports will be submitted to the
Board for approval on 8 March 2016.


* Consolidated revenues are € 1,047.7 million, up by 6.1% compared to the
preceding year. International sales, which represent 79.8% of total sales,
grow by 8.8% while sales in Italy, at 20.2% of the total, decrease by 3.3%.

* EBITDA (1)is € 317.0 million, an increase of 15.8% over 2014, with a margin
of 30.3% of sales thanks to gross margin improvement and the relatively low
increase in operational costs.
* Operating income , at 26.6% of sales, is € 278.5 million, an increase of
20.6% over the preceding year.
* Net income, at 19.0% of sales, is € 198.8 million, an increase of 23.3%
over 2014.
* Net financial position (2)at 31 December 2015 records a net debt of € 88.7
million, a reduction of € 97.3 million compared to that at 31 December
2014, after payment of dividends for an amount of € 110.8
million.Shareholders' equity increases to € 870.0 million.

Earnings before interest, taxes, depreciation and amortization.
Cash and short-term financial investments less bank overdrafts and
medium/long-term loans which include the measurement at fair value of hedging

Management comments

"2015 was another growth year for our group due both to the positive
development of our revenues and to the further improvement of our
profitability. All business segments and the main corporate products
contributed to these results. The internationalization of our business
dedicated to rare diseases went ahead with new subsidiaries in Brazil, Mexico
and Colombia. Furthermore, Carbaglu® was authorized for sale by Health Canada
for the treatment of hyperammonaemia due to the deficiency of the hepatic
enzyme NAGS in pediatric and adult patients. In May the new product Virirec®,
indicated for the treatment of erectile dysfunction, was successfully
launched in Spain. In September Erytech Pharma, a French company with which
we have an exclusive licensing agreement, submitted a centralized Marketing
Authorization Application to the European Medicines Agency (EMA) for Graspa®
for the treatment of patients with acute lymphoblastic leukemia (ALL)."
"In coming years we will continue to develop the business, both by growing the
existing product portfolio as well as through acquisitions of products or
companies" continued Giovanni Recordati. "In 2016 our targets are to achieve
sales ranging from € 1,070 million to € 1,100 million, EBIT of between € 290
and 300 million and net income of between € 205 and 215 million."

Declaration by the Manager responsible for preparing the Company's financial

The manager responsible for preparing the company's financial reports Fritz
Squindo declares, pursuant to paragraph 2 of Article 154-bis
of the Consolidated Law on Finance, that the accounting information contained
in this press release corresponds to the document results, books and
accounting records.

Conference call

Recordati will be hosting aconference call
today 11 February 2016
at 4.00 pm Italian time (3.00 pm London time, 10.00 am New York time). The
dial-in numbers are:

Italy +39 02 8058811, toll free 800 213 858
UK +44 1 212818003, toll free 800 0156384
USA +1 718 7058794, toll free 855 2656959
France +33 170918703
Germany +49 69 255114451

Callers are invited to dial-in 10 minutes before conference time. If
conference operator assistance is required during the connection please digit
* followed by 0 or call +39 02 8061371. A recording of the conference call
will be placed on the website www.recordati.com.

A set of slides which will be referred to during the call will be available on
our website www.recordati.com under Investors/Company Presentations.


, established in 1926, is an international pharmaceutical group, listed on the
Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271), with a total staff of around 4,000, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. Headquartered in
Milan, Italy, Recordati has operations in the main European countries, in
Russia, in other Central and Eastern European countries, in Turkey, in North
Africa and in the United States of America. An efficient field force of
medical representatives promotes a wide range of innovative pharmaceuticals,
both proprietary and under license, in a number of therapeutic areas
including a specialized business dedicated to treatments for rare diseases.
Recordati is a partner of choice for new product licenses for its
territories. Recordati is committed to the research and development of new
specialties within the urogenital therapeutic area and of treatments for rare
diseases. Consolidated revenue for 2014 was € 987.4 million, operating
income was € 231.0 million and net income was € 161.2 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Media Relations
Marianne Tatschke
Studio Noris Morano

(39)0276004736, (39)0276004745

Statements contained in this release, other than historical facts, are
"forward-looking statements" (as such term is defined in the Private
Securities Litigation Reform Act of 1995). These statements are based on
currently available information, on current best estimates, and on
assumptions believed to be reasonable. This information, these estimates and
assumptions may prove to be incomplete or erroneous, and involve numerous
risks and uncertainties, beyond the Company's control. Hence, actual results
may differ materially from those expressed or implied by such forward-looking
statements. All mentions and descriptions of Recordati products are intended
solely as information on the general nature of the company's activities and
are not intended to indicate the advisability of administering any product in
any particular insta


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RECORDATI via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.